Emergent Health Corp (OTC:EMGE)

From April 2011:

KING OF PRUSSIA, Pa., April 26, 2011 (GLOBE NEWSWIRE) -- Emergent Health Corp. (the "Company") (Pink Sheets:EMGE) is pleased to update its historic unaudited financial statements and Management's Discussion and Analysis of Financial Condition for first quarter of 2011 compared to first quarter of 2010.

First quarter unaudited revenues for January 1, 2011 to March 31, 2011 were $71,296.62 compared to $53,853.11 for January 1 to March 31, 2010. This is an approximate 32% increase. The Company attributes this to increased International demand for new products, and while no guarantee it will continue, efforts in these markets continue.

Net profit unaudited before taxes for the same periods January 1, 2011 to March 31, 2011 were $30,383.33 compared to $16,260.32 for the period January 1, 2010 to March 31, 2010. This is an approximate 87% increase and is attributed to tight cost control. These margins could decrease due to possible need for additional staff in the future.

The Company's total assets as of March 31, 2011 were $435,000.00 compared to $378,081.00 as of March 31, 2010. The Company's cash position was $405,556.00 as of March 31, 2011 compared to $362,101.00 as of March 31, 2010.

The Company continues to have no long term debt and believes it is adequately funded for the balance of this year

Our licensor has received a patent for its hair growth product and we are reviewing ways to initiate a marketing process for that. We
hope to have a product related to hair growth and grooming available in 2011. Other new products planned for 2011 are:

1. Multi Vitamin with Stem Cell Support for Health Food Stores and a second brand for a possible referral marketing endeavor. This is a totally untapped
niche within the estimated Trillion dollar multi-vitamin field.

2. A topical gel for pain relief. This product is clear, odorless, stain free and fast acting.

The Company continues to develop markets and an Infomercial began airing in the third quarter. We are reviewing future Infomercial plans.

Likewise, S.E. Asia sales continue to develop. The Company has been given a bright forecast for 2011 and beyond, but prefers to wait until further orders
materialize. As indicated prior, Emergent Health™ Vita-Stim was approved in Cambodia for resale and this past quarter EmergentO2™ Water Oxygenator has
been approved for resale there also. We are currently working on approvals in several other S. E. Asia countries.

The Company continues negotiations to partner with a group of networkers to provide capital to a jointly owned private endeavor to market an Anti-Aging
product also to be revealed in 2011, if and when concluded.

The Company is also exploring a unique combination of Circumin and Vita-Stim for cardio and cancer nutritional support.

We continue to aggressively explore all possible ways to expand sales for Emergent Health™ Physician Formulated Vita-Stim, Neuvitale™ Life Support,
EmergentO2™ Water Oxygenator and Hungarest® Diet &Energy Aid. The Company believes it remains sufficiently capitalized to continue its current
course for the upcoming year 2011 and intends to do all possible to increase shareholder value.

Respectfully Submitted,
John V. Cappello, CFO

In May 2010, the SEC filed an action against those parties responsible for the “pump and dump” of our stock. In July 2010 the SEC sent a letter to our Counsel indicating they were recommending no action against the Company.

In August 2010 a broker dealer filed a Form 211 to assist the Company to resume normal trading off the Grey Market. A FINRA letter of comment was received in September 2010 with nine comments and the Company provided the broker dealer with answers to all comments and these were submitted to FINRA in
October 2010.

On December 27, 2010 FINRA responded with just two comments. These were answered on December 28, 2010 and we were advised by the broker dealer our response was faxed to FINRA on December 31, 2010. We are encouraged and cautiously optimistic that we have met all disclosure requirements for resumption of normal trading with “bids” and “asks”, hopefully in 2011.

KING OF PRUSSIA, Pa., Feb. 28, 2011 (GLOBE NEWSWIRE) -- Emergent Health Corp. (Pink Sheets:EMGE) (the "Company") is pleased to announce our securities have been approved to be traded by market makers as of February 2011. This means our stock is once again able to trade with "bids" and "asks" on the OTC Market, formerly known as Pink Sheets. We are excited about this development and hope it will renew confidence in shareholders that the Company is one with a long term vision for success with ongoing stock trading transparency intentions.

Our initial market maker is B.M.A. Securities (BMA). BMA is a FINRA member full service brokerage firm. BMA is located in Rolling Hill Estates, CA and offers a wide array of financial services. These include: market making, institutional trading, investment banking, advisory and consulting services.

We continue our efforts to increase both domestic and international sales. Our Physician Formulated Vita-Stim product promotes stem cell nutrition naturally. It was approved by the Cambodia Ministry of Health for resale the last quarter of 2010. Sales there, and in other parts of S.E. Asia, are in a developmental stage.

KING OF PRUSSIA, Pa., Feb. 28, 2011 (GLOBE NEWSWIRE) -- Emergent Health Corp. (Pink Sheets:EMGE) (the "Company") is pleased to announce our securities have been approved to be traded by market makers as of February 2011. This means our stock is once again able to trade with "bids" and "asks" on the OTC Market, formerly known as Pink Sheets. We are excited about this development and hope it will renew confidence in shareholders that the Company is one with a long term vision for success with ongoing stock trading transparency intentions.

Our initial market maker is B.M.A. Securities (BMA). BMA is a FINRA member full service brokerage firm. BMA is located in Rolling Hill Estates, CA and offers a wide array of financial services. These include: market making, institutional trading, investment banking, advisory and consulting services.